RT Journal Article
SR Electronic
T1 Individual effect of diet on postprandial glycemic response and its relationship with gut microbiome profile in healthy subjects: protocol for a series of randomized N-of-1 trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.22.23300429
DO 10.1101/2023.12.22.23300429
A1 Zamparette, C.P.
A1 Teixeira, B.L.
A1 Cruz, G.N.F.
A1 Filho, V. B.
A1 De Oliveira, L.F.V.
YR 2023
UL http://medrxiv.org/content/early/2023/12/24/2023.12.22.23300429.abstract
AB Background Type 2 diabetes causes over a million deaths annually, ranking in the top ten causes of death worldwide. Glycemic control through dietary adequacy is essential for treatment success and disease prevention. Recent evidence indicates that the glycemic response to various foods varies from individual to individual. The intestinal microbiome is seen as a potential key player, mediating the effect of foods on glycemic response. By design, however, most published studies cannot separate variation in the individual treatment effects (ITE) of different diets from within-individual variability of glycemic responses. In this context, the present study aims to assess the heterogeneity in the ITE of diet on glycemic response and investigate the relevance of the intestinal microbiome profile as a predictor of this heterogeneity.Methods This study is a series of N-of-1 randomized clinical trials. Each participant will undergo five treatment cycles of two prescribed diets (low-carb versus vegan) in one of two randomly chosen treatment sequences (ABBABAABBA or BAABABBAAB). The primary outcome is the positive incremental area-under-the-curve (iAUC) of the postprandial interstitial fluid glucose measured within 2 hours of meal consumption. The trial plans to recruit 80 healthy volunteers with ages between 18 and 60. Fecal samples will be collected at baseline for microbiome analysis by metagenomics shotgun technique. Random effects linear models will be used for the primary analysis.Discussion While significant variation of individual effects warrants personalized interventions, it is well-known that glycemic responses to the same food, in the same individual, vary from occasion to occasion. Yet, most clinical studies are based on designs that are incapable of separating ITE variation from within-individual variability. This is a major limitation since the personalization of dietary interventions is only justified by clinically relevant heterogeneity of individual-level effects. In this study, if significant ITE variation is indeed observed, then we will also be able to estimate the relationship between the intestinal microbiome and the expected diet effects. This is essential to identify predictive biomarkers, which can identify those who intrinsically benefit the most from which diet, going beyond pure associations with glycemic response. Conversely, observing negligible ITE variation in a large series of N-of-1 trials would cast major doubts on the relevance of personalizing dietary interventions for glycemic control. Therefore, the present study represents a major step toward understanding the clinical value of microbiome-driven precision nutrition.Competing Interest StatementThe authors declared the following potential conflicts of interest concerning the research, authorship and publication of this protocol: Luiz Felipe Valter de Oliveira is the BiomeHub Technologies startup CEO, in which the project was designed and will be conducted. Bianca Luise Teixeira and Giuliano Netto Flores Cruz are employees at BiomeHub and will actively work on the project. Caetana Paes Zamparette and Vilmar Benetti Filho receive CNPq scholarships for the development of this project at BiomeHub and will actively contribute to the project.Clinical TrialNCT06051318Funding StatementThis study will be funded by the biotechnology company BiomeHub and partially supported by the National Committee for Scientific and Technological Development (CNPq) with two scholarships from the Human Resources Training Program in Strategic Areas (RHAE), process number 424464/2021-7. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Committee on Ethics in Research - Center for Oncological Research -CEPON Conclusions or Pending and List of Inadequacies: All the pending issues presented in the Substantiated Opinion CEP No. 6,112,074, dated June 12, 2023, have been duly addressed and approved. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCGMContinuous Glucose MonitorFDRFalse Discovery RateITEIndividual treatment effectsTMCTrial Management CommitteeiAUCincremental Area-Under-the-Curve